{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104105","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.104311+00:00","generated_at":"2026-05-15T13:41:58.540939+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Erasca reports Q4 2025 net loss $29.1M; ERAS-0015 shows early partial responses","bullets":["Net loss per share $(0.10) for Q4 2025 vs. $(0.11) in Q4 2024; full-year net loss $124.5M ($0.44/share).","Cash, equivalents, and marketable securities $341.8M at Dec 31, 2025; pro forma $434M after Jan 2026 $259M upsized financing.","ERAS-0015 showed confirmed partial responses across multiple RAS-mutant tumors at 8 mg QD with favorable safety and PK.","R&D expenses $23.2M in Q4, down from $26.1M YoY; total R&D $92.9M for FY 2025 vs $115.4M in FY 2024.","Expanded ERAS-0015 license to worldwide rights; composition of matter patents issued for ERAS-0015 and ERAS-4001."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104105","json":"https://secwatch.observer/filing/0001193125-26-104105.json","markdown":"https://secwatch.observer/filing/0001193125-26-104105.md","text":"https://secwatch.observer/filing/0001193125-26-104105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/0001193125-26-104105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/eras-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:41:58.540939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2e8e0a4653846c2fa4e4db8f33e330220d36a48","claim":"Erasca, Inc. reported Q4 2025 results: net income -29.1 million, EPS -0.10.","evidence_excerpt":"Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/0001193125-26-104105-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2025"},{"label":"Net income","value":"-29.1 million"},{"label":"EPS","value":"-0.10"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}